Legislation To Let Doctors Prescribe A Form Of Psilocybin After Federal Approval Becomes Law In Colorado, But Is Vetoed In Virginia - Marijuana Moment
Colorado has enacted a law allowing doctors to prescribe psilocybin after federal approval, while Virginia vetoed similar legislation. This creates a state-level pathway for psilocybin prescriptions contingent on FDA/DEA rescheduling, impacting pharmaceutical manufacturers and compounders.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmaceutical manufacturers, API suppliers, and 503B outsourcing facilities involved in controlled substances or psychedelic drug development. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; no immediate deadline but proactive monitoring recommended ahead of federal action.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Colorado law (HB 23-1340) permits prescribing psilocybin once federally approved; Virginia veto blocks similar action. No immediate federal change, but state law signals potential future market and regulatory shifts.
Who it affects
Pharmaceutical manufacturers, API suppliers, and 503B outsourcing facilities involved in controlled substances or psychedelic drug development.
What you must do
Monitor FDA/DEA rescheduling of psilocybin; assess supply chain readiness for potential Schedule II or III classification; review Colorado-specific compliance requirements if operating in that state.
Deadline
Ongoing; no immediate deadline but proactive monitoring recommended ahead of federal action.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)